Rajeev Saggar
Chief Tech/Sci/R&D Officer at LIQUIDIA CORPORATION
Net worth: 3 M $ as of 2024-03-30
Profile
Rajeev Saggar is currently the Chief Medical Officer at Liquidia Corp.
Prior to this, he was the Vice President of Clinical Development at Theravance Biopharma US, Inc. from 2021 to 2022.
He also served as the Medical Director for Pulmonary Hypertension & Fibrosis at The Banner-University Medical Center.
Dr. Saggar holds a doctorate degree from the University of California, Irvine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
LIQUIDIA CORPORATION
0.28% | 2024-04-18 | 211,672 ( 0.28% ) | 3 M $ | 2024-03-30 |
Rajeev Saggar active positions
| Companies | Position | Start |
|---|---|---|
| LIQUIDIA CORPORATION | Chief Tech/Sci/R&D Officer | 2022-07-17 |
Former positions of Rajeev Saggar
| Companies | Position | End |
|---|---|---|
Theravance Biopharma US, Inc.
 Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 2022-06-30 |
| The Banner-University Medical Center | Corporate Officer/Principal | - |
Training of Rajeev Saggar
| University of California, Irvine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| LIQUIDIA CORPORATION | Health Technology |
| Private companies | 1 |
|---|---|
Theravance Biopharma US, Inc.
Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Commercial Services |
- Stock Market
- Insiders
- Rajeev Saggar
